نتایج جستجو برای: aripiprazole

تعداد نتایج: 1812  

2016
Hulya Ertekin Yusuf Haydar Ertekin Basak Sahin Sinan Yayla Ersin Turkyilmaz Medine Kara

Turner Syndrome (TS) is the most common chromosomal anomaly in women. Its psychiatric manifestations have not been clearly defined. Occurrence of schizophrenia is higher in patients with TS than in the normal population. The literature has reported instances associating stuttering as a side effect of antipsychotic drugs, particularly clozapine-induced stuttering. We found only one case report d...

2015
Adarsh VOHRA

Many drugs including anti-depressants and anti-psychotics are known to cause excessive sweating (hyperhidrosis). Hyperhidrosis may be caused by drugs acting at the hypothalamus, spinal thermoregulatory centres, and sympathetic ganglia or at the eccrine-neuroeffector junction. Hyperhidrosis can be distressing and embarrassing symptom, which if not addressed properly, may lead to non-concordance ...

2011
Alexander C. Tsai Nicholas Z. Rosenlicht Jon N. Jureidini Peter I. Parry Glen I. Spielmans David Healy

BACKGROUND Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005. Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance treatment of bipolar disorder an...

2015
Marc De Hert Anna Eramo Wally Landsberg Dusan Kostic Lan-Feng Tsai Ross A Baker

PURPOSE To assess the efficacy and safety of aripiprazole once-monthly 400 mg (AOM 400), an extended-release injectable suspension of aripiprazole, in obese and nonobese patients. PATIENTS AND METHODS This post hoc analysis of a 38-week randomized, double-blind, active-controlled, noninferiority study (NCT00706654) compared the clinical profile of AOM 400 in obese (body mass index [BMI] ≥30 k...

Journal: :Journal of Clinical Psychopharmacology 2017

Journal: :European Psychiatry 2023

Introduction Aripiprazole is a third generation atypical antipsychotic and dopamine serotonin system stabilizer, effective against positive negative symptoms of schizophrenia. Within the group antipsychotics, aripiprazole shows relatively benign safety profile (e.g. lower metabolic impact, mild effect on cardiovascular parameters), although reported rate extrapyramidal side effects measurable. ...

2014
Eiji Kirino

Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiven...

2009
Salvatore Gentile

Aripiprazole is a relatively novel second-generation antipsychotic belonging to the chemical class of benzisoxazole derivatives and is characterized by a unique pharmacological profile which suggests that the drug acts as a dopamine-serotonin system stabilizer. Whereas all previously available antipsychotics are antagonists at D(2) receptors, aripiprazole is the only available partial agonist a...

Journal: :Journal of analytical toxicology 2015
Louise Skov Sys Stybe Johansen Kristian Linnet

Postmortem femoral blood concentrations of the antipsychotic drugs aripiprazole, chlorprothixene and its metabolite, and quetiapine were determined by LC-MS-MS in 25 cases for aripiprazole and 60 cases each for chlorprothixene and quetiapine. For cases where the cause of death was not related to the considered drugs, the following blood concentration intervals (10-90 percentiles) were observed:...

Journal: :Pharmacology, biochemistry, and behavior 2014
Michael De Santis Bo Pan Jiamei Lian Xu-Feng Huang Chao Deng

Following on the success of Aripiprazole with its high clinical efficacy and minimal side effects, further antipsychotic drugs (such as Bifeprunox) have been developed based on the same dopamine D2 partial agonist pharmacological profile as Aripiprazole. However clinical trials of Bifeprunox have found differing results to that of its predecessor, without the same significant clinical efficacy....

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید